<DOC>
	<DOCNO>NCT01410227</DOCNO>
	<brief_summary>The purpose Phase 3 study ass pharmacokinetics rVWF : rFVIII rVWF , assess safety efficacy rVWF : rFVIII rVWF treatment bleed event subject severe hereditary von Willebrand disease ( VWD ) .</brief_summary>
	<brief_title>Pharmacokinetics , Safety Efficacy Recombinant Von Willebrand Factor ( rVWF ) Treatment Bleeding Episodes Von Willebrand Disease ( VWD )</brief_title>
	<detailed_description />
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Participant diagnose : 1 . Type 1 ( Von Willebrand factor : Ristocetin cofactor activity ( VWF : RCo ) &lt; 20 IU/dL ) , 2 . Type 2A ( VWF : RCo &lt; 20 IU/dL ) , Type 2B ( diagnose genotype ) , Type 2N ( Factor VIII activity ( FVIII : C ) &lt; 10 % historically document genetics ) , Type 2M , 3 . Type 3 ( Von Willebrand factor antigen ( VWF : Ag ) ≤ 3 IU/dL ) , 4 . Severe Von Willebrand disease ( VWD ) history require substitution therapy von Willebrand factor concentrate control bleed Participant , participate treatment bleed episode , minimum 1 document bleed ( medical history ) require VWF coagulation factor replacement therapy previous 12 month prior enrollment . Participant Karnofsky score ≥ 60 % Participant least 18 old 65 year age enrollment If female childbearing potential , participant present negative pregnancy test Participant agree employ adequate birth control measure duration study Participant willing able comply requirement protocol Participant diagnose pseudo VWD another hereditary acquire coagulation disorder VWD ( eg qualitative quantitative platelet disorder elevate PT/international normalize ratio [ INR ] &gt; 1.4 ) . Participant document history VWF : RCo halflife &lt; 6 hour . Participant history presence VWF inhibitor screen . Participant history presence factor VIII ( FVIII ) inhibitor titer ≥0.4 BU ( Nijmegen assay ) ≥ 0.6 BU ( Bethesda assay ) . Participant known hypersensitivity component study drug , mouse hamster protein . Participant medical history immunological disorder , exclude seasonal allergic rhinitis/conjunctivitis , mild asthma , food allergy animal allergy . Participant medical history thromboembolic event . Participant HIV positive absolute CD4 count &lt; 200/mm3 . Participant diagnose cardiovascular disease ( New York Heart Association [ NYHA ] class 14 . Participant acute illness ( eg , influenza , flulike syndrome , allergic rhinitis/conjunctivitis , nonseasonal asthma ) screening . Participant diagnose significant liver disease evidence follow : serum alanine aminotransferase ( ALT ) 5 time upper limit normal ; hypoalbuminemia ; portal vein hypertension ( eg , presence otherwise unexplained splenomegaly , history esophageal varix ) . Participant diagnose renal disease , serum creatinine level ≥2 mg/dL . In judgment investigator , participant another clinically significant concomitant disease ( eg , uncontrolled hypertension ) may pose additional risk participant . Participant treat immunomodulatory drug , exclude topical treatment ( eg , ointment , nasal spray ) , within 30 day prior enrollment Participant pregnant lactating time enrollment . Participant participate another clinical study involve IP investigational device within 30 day prior enrollment schedule participate another clinical study involve investigational product investigational device course study . Participant history drug alcohol abuse within 2 year prior enrollment . Participant progressive fatal disease and/or life expectancy le 3 month . Participant identify investigator unable unwilling cooperate study procedure . Participant suffers mental condition render him/her unable understand nature , scope possible consequence study and/or evidence uncooperative attitude . Participant prison compulsory detention regulatory and/or juridical order</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>